Overview
US gene therapy firm's fiscal Q3 net loss narrowed from prior year as expenses fell
R&D and G&A expenses declined yr/yr as BB-301 clinical development advanced
Result Drivers
The Company incurred $6.3 million of research and development expenses which was in line with $6.5 million for the comparable quarter ended March 31, 2025.
Company press release: ID:nGNX4vzvpx
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.24
Q3 Net Income
-$11.90 mln
Q3 Operating Income
-$13.60 mln
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Benitec Biopharma Inc is $27.00, about 131.8% above its May 13 closing price of $11.65
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
